We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Blood Marker Predicts Prognosis of Abdominal Infection

By HospiMedica staff writers
Posted on 27 Feb 2007
Monitoring blood levels of a compound known as procalcitonin in patients with peritonitis (a serious intra-abdominal infection) could help identify patients at increased risk of organ failure and death.

Organ failure related to blood stream infection (sepsis) is the leading cause of death in surgical intensive care units, accounting for up to 60% of deaths, according to an article in the February 2007 issue of Archives of Surgery. More...
Peritonitis, infection of the layer of tissue lining the abdominal wall, is one of the most important sources of abdominal sepsis. Secondary peritonitis occurs as a consequence of another condition, such as a puncture in the gastrointestinal tract that allows the spread of bacteria, and generally this underlying condition must be treated surgically. However, continuing or new-onset abdominal sepsis continues to be a major problem for these patients following surgery, placing them at risk of multi-organ dysfunction syndrome (failure of two or more organ systems) and death.

Facing this clinical dilemma, there is major interest in the search for an optimum diagnostic tool for an early, noninvasive, and reliable diagnosis of abdominal infections and sepsis, the authors wrote. Currently, these conditions are diagnosed with imaging procedures and guided aspiration (suction) techniques. An accurate and readily available biochemical marker for identifying patients at risk for abdominal infections would definitely contribute to easier and safer diagnosis.

Bettina M. Rau, M.D., from the University of the Saarland, (Homber/Saar, Germany), and colleagues enrolled 82 patients with secondary peritonitis between 1999 and 2004 in a study to determine whether procalcitonin could be such a marker.

Procalcitonin, an inactive precursor to a hormone known as calcitonin, has been shown to be more prevalent in patients with bacterial and fungal infections, and sepsis. Bacterial specimens were obtained from the abdomens of all participants, as were other tissue cultures when sepsis was suspected. The patients were monitored from within 96 hours of their first symptoms to a maximum of 21 days for levels of procalcitonin and another marker of inflammation, C-reactive protein, and for signs of lung or kidney failure.

Over the follow-up period, 42 patients developed lung failure, 25 developed kidney failure, 35 had multiorgan dysfunction syndrome (31 cases of which were related to sepsis) and nine died. Procalcitonin concentrations were most closely correlated with the development of septic multi-organ dysfunction syndrome, with peak levels occurring early after symptom onset or during the immediate post-operative course, the authors wrote. No such correlation was observed for C-reactive protein.

It was possible to predict multi-organ dysfunction syndrome by assessing procalcitonin levels on the first two days following surgery; those with values of 10 ng per ml on two consecutive days were at higher risk. Persisting procalcitonin levels greater than one ng per ml beyond the first week after disease onset strongly indicated non-survival and were significantly better than C-reactive protein in assessing overall prognosis, they continued.

In summary, the present prospective, international multi-center study shows that monitoring of procalcitonin levels is a fast and reliable approach to assessing severe septic complications and overall prognosis in patients with secondary peritonitis, the authors concluded. This single-test marker improves stratification of patients who will develop clinically relevant complications.


Related Links:
University of the Saarland

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.